Speaker Credentials
OMS-II
Speaker Credentials
BS
College
Dr. Kiran C. Patel College of Osteopathic Medicine, DO
Medical Specialty
Internal Medicine
Format
Poster
Start Date
November 2024
End Date
November 2024
Track
3
Abstract
Objective: The study aims to explore the therapeutic potential of dual GIP/GLP-1 agonist tirzepatide in managing obesity and its associated manifestations, including obstructive sleep apnea (OSA), hidradenitis suppurativa (HS), and obesity-associated cancer (OAC) risks. Background: OSA and HS are the associated comorbidities noted in persons with obesity. Obesity has been associated with an increased risk of cancers, such as breast cancer. Reducing obesity could improve these conditions. Tirzepatide has demonstrated efficacy in reducing body weight, but its benefits in obesity-related conditions and cancer risk need further investigation. Methods: Data was synthesized from peer-reviewed literature on tirzepatide. Additional sources were identified through systematic searches of PubMed, Google Scholar, and clinical trial registries using the keywords OSA, HS, cancer, and tirzepatide. Results: Clinical studies on tirzepatide show promising results. For sleep apnea, tirzepatide significantly reduced apnea and hypopnea events per hour, both with and without CPAP therapy, compared to placebos. Secondary endpoints improved significantly, including body weight, hypoxic burden, hsCRP concentration, systolic blood pressure, and sleep-related outcomes. Ongoing trials, such as NCT06301256, evaluate tirzepatide for HS, with evidence suggesting GLP-RAs can decrease flare-ups. In the preclinical model, tirzepatide mitigated obesity-driven metabolic changes and suppressed mammary tumor growth. A clinical trial, NCT06517212, is underway that investigates whether tirzepatide-induced weight loss can inhibit metastatic disease development in high-risk early breast cancer patients. Conclusion: Tirzepatide has demonstrated a promising role in OSA treatment through weight management. Ongoing trials will provide further insights into its effects on HS and cancer risk in persons with obesity.
Included in
Endocrinology, Diabetes, and Metabolism Commons, Oncology Commons, Pharmaceutics and Drug Design Commons, Pulmonology Commons
Evaluating Tirzepatide's Therapeutic Potential in Mitigating Obesity-Associated Comorbidities
Objective: The study aims to explore the therapeutic potential of dual GIP/GLP-1 agonist tirzepatide in managing obesity and its associated manifestations, including obstructive sleep apnea (OSA), hidradenitis suppurativa (HS), and obesity-associated cancer (OAC) risks. Background: OSA and HS are the associated comorbidities noted in persons with obesity. Obesity has been associated with an increased risk of cancers, such as breast cancer. Reducing obesity could improve these conditions. Tirzepatide has demonstrated efficacy in reducing body weight, but its benefits in obesity-related conditions and cancer risk need further investigation. Methods: Data was synthesized from peer-reviewed literature on tirzepatide. Additional sources were identified through systematic searches of PubMed, Google Scholar, and clinical trial registries using the keywords OSA, HS, cancer, and tirzepatide. Results: Clinical studies on tirzepatide show promising results. For sleep apnea, tirzepatide significantly reduced apnea and hypopnea events per hour, both with and without CPAP therapy, compared to placebos. Secondary endpoints improved significantly, including body weight, hypoxic burden, hsCRP concentration, systolic blood pressure, and sleep-related outcomes. Ongoing trials, such as NCT06301256, evaluate tirzepatide for HS, with evidence suggesting GLP-RAs can decrease flare-ups. In the preclinical model, tirzepatide mitigated obesity-driven metabolic changes and suppressed mammary tumor growth. A clinical trial, NCT06517212, is underway that investigates whether tirzepatide-induced weight loss can inhibit metastatic disease development in high-risk early breast cancer patients. Conclusion: Tirzepatide has demonstrated a promising role in OSA treatment through weight management. Ongoing trials will provide further insights into its effects on HS and cancer risk in persons with obesity.